课题基金 / 基金详情

项目摘要

项目成果

MICHAEL T MCMANUS的其他基金

相似基金

相关文献

中文摘要
翻译
这项研究的广泛的长期目标是建立exRNA生物分布的结论性支持, 摄取,并在活体小鼠的广泛组织中发挥作用。这可能是由于新的基因 研究人员实验室开发的技术和试剂。这些因素包括但不限于:遗传 切除蠕虫exRNA转运蛋白SIDI的两个小鼠同源物(SID 1/2); 小鼠microRNA exRNA宿主;以及小鼠中exRNA活性的模块化和高度适应性阳性传感器, 活组织 有必要共同努力开发exRNA工具和试剂,以进一步探索这种新的 这是理解人类生物学和开发治疗干预策略的范例。 可以说,小鼠模型代表了最好的哺乳动物模型,因为它与人类模型有很强的相似性。 发展和疾病,以及有形动物资源的日益丰富。然而 开发新的小鼠遗传模型需要特殊的技能,有时使用工匠协议, 对于大多数实验室来说,采用这种方法并不划算。 要求为小鼠遗传学核心提供资金,以支持U19提案中的三名研究人员, 更广泛地说,整个细胞外RNA通讯计划。这个核心建立在现有的 高效的结构,促进规模经济的遗传学管道集成到这个核心。
英文摘要
The broad, long-term objectives of this study is to establish conclusive support for exRNA biodistribution, uptake, and function in a wide range of tissues in the living mouse. This is possible due to new genetic technologies and reagents developed in the investigators labs. These include but are not limited to: genetic ablation of the two mouse homologs (SID1/2) of the worm exRNA transporter SIDI; genetic ablation of a host of mouse microRNA exRNAs; and a modular and highly adaptable positive sensor for exRNA activity in live tissues. There is a need to for a concerted effort to develop exRNA tools and reagents to further explore this novel paradigm for understanding human biology and the development of therapeutic intervention strategies. Arguably, mouse models represent the best mammalian models, given the strong parallel to human development and disease, and the increasing abundance of tangible animal resources. However the development of new mouse genetic models requires special skills, sometimes using artisan protocols, and is not cost effective for most labs to adopt. Funding is requested for a mouse genetics core to support three investigators in this U19 proposal, and more broadly, the entire Extracellular RNA Communication Initiative. This Core builds upon an existing highly efficient structure, promoting an economy of scale genetics pipeline integrated into this core.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Orthogonal CRISPR GEMMs
iSTAR Tregs
Illuminating gene therapy
Functional Networks for Persister Cell Sensitivities
海外基金